Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS

Background: Influx of innovative therapies and dramatic rise in prices have been prompting value-driven decision-making. Both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have independently proposed value assessment frameworks. Objectives: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qian, Feng, Mei, Li, Youping, Lang, Jinyi, Wei, Hua, Yu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775497/
https://www.ncbi.nlm.nih.gov/pubmed/33390946
http://dx.doi.org/10.3389/fphar.2020.574511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775497/
https://www.ncbi.nlm.nih.gov/pubmed/33390946
http://dx.doi.org/10.3389/fphar.2020.574511

Ejemplares similares